Randee Mclain, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 10201 Mission Gorge Rd Ste O, Santee, CA 92071 Phone: 619-383-6868 |
Lisa Jayne Read, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 9483 Lake Canyon Rd, Santee, CA 92071 Phone: 619-749-3203 |
Ruth V Sigler, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 8760 Cuyamaca St, Suite 207, Santee, CA 92071 Phone: 619-448-0133 Fax: 619-448-0132 |
Mr. David Squire, LCSQ Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 10641 Aristocrat Ct, Santee, CA 92071 Phone: 619-549-2963 Fax: 619-334-0005 |
Marsha E Hanna Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 5288 Bella Vista St, Santee, CA 92071 Phone: 619-504-6681 |
Joseph Salvati, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 10033 Beck Dr, Santee, CA 92071 Phone: 619-393-1907 |
Danielle Humphrey, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 8007 Calle Fanita, Santee, CA 92071 Phone: 619-218-8746 |
News Archive
The European League Against Rheumatism, EULAR, has published recommendations around rheumatic immune-related adverse events caused by cancer treatment with checkpoint inhibitors.
The University of North Carolina at Chapel Hill received two separate grants from the U.S. Food and Drug Administration and the National Institutes of Health today as part of an on-going interagency partnership. UNC will house two of 14 Tobacco Centers of Regulatory Science, which are receiving a total of up to $53 million for tobacco-related research in fiscal year 2013.
According to a new study published in the October issue of the Journal of the American College of Surgeons, although breast-conserving surgery (BCS), commonly known as lumpectomy, is increasingly being used to treat older women with nonmetastatic invasive breast cancer, there are still significant socioeconomic and geographic disparities in the use of this type of therapy.
Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), a global company pioneering the development of a cell implant therapy to treat diabetes, today announced that a binding subscription agreement has been executed in relation to share placement with Jiangsu Aosaikang Pharmaceutical Co., Ltd. ("ASK"). The proposed placement is for the issue of 14,334,080 LCT shares at A$0.12 per share, to raise A$1.72m. This represents a 5% equity stake in LCT, the funds to be received by LCT from ASK not later than 4 March 2011.
The time needed for breast cancer metastases (secondary lesions caused by cells that have escaped from the original tumor) to develop varies between patients, and little is known about the mechanisms that govern latency (the dormant state of cells that have already spread through the body).
› Verified 7 days ago